Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial.

Journal: Kidney medicine
Published Date: Dec 18, 2023

Abstract

RATIONALE & OBJECTIVE: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with a greater risk of kidney failure and cardiovascular disease. In EMPA-REG OUTCOME, empagliflozin was associated with slower kidney disease progression. This post hoc analysis evaluated the effect of empagliflozin (pooled doses) on the prevalence of a "rapid decliner" phenotype, defined by an annual estimated glomerular filtration rate (eGFR) decline of >3 mL/min/1.73 m.

Authors

  • Samy Hadjadj
    Institut du thorax, INSERM, CNRS, Université Nantes, CHU Nantes, Nantes, France.
  • Mark E Cooper
    Department of Diabetes, Monash University, Melbourne, Australia.
  • Dominik Steubl
    Boehringer Ingelheim International GmbH, Ingelheim, Germany, and Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
  • Michaela Petrini
    Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.
  • Stefan Hantel
    Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Michaela Mattheus
    Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
  • Christoph Wanner
    Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
  • Merlin C Thomas
    Department of Diabetes, Monash University, Melbourne, Australia.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals